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Medical writers and translators need information of three kinds: 
conceptual, contextual and textual. When in possession of this information, 
they can progressively improve their efficiency. Textual genre has proved to 
be useful to linguistic mediators of professional texts, providing them with 
the communicative and textual competence required. I suggest that the 
scope of textual genre can usefully be widened to include the notion of 
genre systems. This notion can be particularly useful for obtaining 
contextual information and understanding complex communicative 
activities in professional groups and can help enhance the professional 
competence of medical writers and translators. This paper has a two-fold 
objective: to describe the dynamic continuum of medical communication 
that operates in the genre system constituted by product information genres 
in the pharmaceutical sector also considering the restraints, genre 
conventions and sequence imposed by metagenres; and to illustrate the 
intralinguistic genre shift translation process that takes place between the 
summary of product characteristics and the package leaflet. 
1. Introduction 
This paper builds on the tradition of genre studies and the work of the 
GENTT (Textual Genres for Translation) research group1 by arguing that 
some genres form sets of interdependent genres or genre systems as a 
means of performing complex social actions, and that the scope of textual 
genre analysis can usefully be widened to include the notion of genre 
systems. 
Acquiring competence in genre and genre systems can be considered 
an effective means of acquiring the abilities needed by medical writers and 
other linguistic mediators of professional texts, like translators, as it 
facilitates their socialization as communicative agents in the medical and 
pharmaceutical sectors. 
I shall concentrate on the communicative process carried out by 
pharmaceutical companies, which is intended to facilitate the prescription 
of the medicine by the competent intermediaries (prescribers, dispensers, 
etc.) and its safe use by patients and the general public. This process is 
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structured in a system of genres that I have called the medicinal product 
information genre system. I shall describe the genre system, the 
interconnections between the genres involved, and the metagenres 
interacting with them, paying particular attention to genre shift (Montalt 
Resurrecció & González Davis, 2007, pp. 162–164) between the summary 
of product characteristics and the package leaflet as an intralingual 
translation process which operates from a more to a less specialized genre. 
2. Genre theory and genre systems in discourse communities 
To be a good specialized writer or linguistic mediator, one of the skills that 
is most evidently required is the ability to understand and produce texts that 
conform to the conventions of the areas of expertise one is working with, 
where the very deep conceptual and contextual knowledge required 
determines the way in which textual and communicative competence 
should be acquired and applied. 
The connection between genres, situated discursive practices and the 
activity of professional groups seems clear, especially if genres are 
considered as devices which combine the formal, socio-communicative and 
cognitive aspects of communication (García Izquierdo, 2005; García 
Izquierdo & Montalt Resurrecció, 2002) and as symbolic structures 
(Schryer & Spoel, 2005) which bring social and textual resources shaped by 
past practitioners forward for current practitioners to use. Studies in genre 
thus, are well positioned a) to produce results that relate texts to their 
professional contexts; b) to help to understand how actions are carried out 
by professional communities; and c) to improve professional linguistic 
practices in professional communities. 
Carolyn Miller’s article “Genre as social action” reconceptualized 
genres as “typified rhetorical actions based in recurrent situations” (1984, p. 
159). This perspective provided a framework for understanding genres in 
terms of exigency, purpose and social action (Devitt, 2000). Reflecting 
Miller’s work (1984) and following Bakhtin’s (1986) insights, researchers 
exploring textual genres in professional settings (Bhatia, 1997; Freedman & 
Medway, 1994) expanded the concept of audience to include their shifting 
and changing social contexts. Studies were published exploring the “fluid 
and dynamic” (Freedman & Medway, 1994, p. 11) nature of genres, how 
genres are related to complex forms of agency (Schryer, 2001), issues of 
power and hierarchy (Giltrow, 2001), and social intentions (Bazerman, 
1994). Concepts such as genre systems (Russell, 2001; Yates & Orlikowski, 
2001, 2002), genre ecologies (Spinuzzi, 2003), family of genres (Ezpeleta 
Piorno & Gamero Pérez, 2004), or genre networks (Schryer & Spoel, 2005) 
emerged to explain the complex interaction of genres in the workplace. The 
theory of genre applied to translation and its correlation with the acquisition 
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of specialized writing and translation competences started also to be 
explored (García Izquierdo, 2005; Montalt Resurrecció, Ezpeleta Piorno, & 
García Izquierdo, 2008; Trosborg, 1997). 
3. Methods and framework 
Our theoretical and descriptive framework of genre systems is informed by 
Bazerman’s (1994) notion of “systems of genres [as] interrelated genres 
that interact with each other in specific settings” (p. 79), and the ongoing 
theoretical development of this view by researchers such as Berkenkotter 
(2001); by the mentioned Russell (2001), Spinuzzi (2003), Yates and 
Olikowski (2001, 2002); and by the GENTT research group (Ezpeleta 
Piorno & Gamero Pérez, 2004; Montalt Resurrecció et al., 2008). Genre 
systems are collections of genres that, despite having different 
characteristics, are related to each other either because they rely on each 
other or because they complement each other in a specific communicative 
context within a specific discourse community.  
The advantage of studying communicative actions using a genre 
system approach is that while genres and genre systems both have 
attributes, a genre system additionally has relational properties that indicate 
links among constituent genres. Whether the multiple operations of a single 
genre or the interactions of various genres are being examined, a genre-
systems approach highlights larger complex and dynamic networks of 
power relations with legal implications and practical consequences. 
Yates and Orlikowski’s (2001, 2002) empirical work on the use of 
genres in organizational practice illustrated the fact that genres are linked to 
each other so as to constitute a structure that coordinates communicative 
actions, and thus they create expectations about the purpose, the content 
and form (including expectations about structuring devices and linguistic 
elements) of the whole system as well as those of its constituent genres. A 
genre system designates the participants involved, who typically initiates 
which genres, and to whom such genres are typically addressed. The 
different genres are also related by their relative timing and location, which 
may be physical or virtual, within the system. Altering the sequence of the 
constituent genres may create a different variant or invalidate the overall 
purpose of the genre system. 
As Schryer and Spoel have pointed out, metagenres help to elaborate 
the legal, ideological and power operations of genre systems, especially 
within institutional contexts, but also between institutions and companies or 
individuals (2005, pp. 256–257). They regulate and reinforce typicality in 
terms of the macro- and microstructure of other genres and provide a 
valuable way to understand the dynamics of institutional interrelations 
among genres. Berkenkotter (2001) has explained that metagenres can be 
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seen as “a mediational means or tool for stabilizing practices” (p. 339). 
Thus metagenres such as institutional guidelines can be constraining and 
enabling, “ruling out certain kinds of expression, endorsing others” 
(Giltrow, 2001, p. 191).  
As previously stated, one of the advantages of studying 
communicative actions using a genre system approach is that they provide 
the linguistic mediators with the contextual and textual knowledge required. 
Genre systems description is particularly useful, then, not only for 
recognizing the aspects of communicative interaction of the whole structure 
but also for understanding the specific function that each of them fulfils and 
the specific textual requirements imposed by the whole communicative 
structure, metagenres included. 
In the following sections I first of all present an overall contextual 
description of the dynamic continuum of medical communication that 
operates in the genre system constituted by product information genres in 
the pharmaceutical sector. To do so, I consider the restraints, genre 
conventions, and sequence imposed by their different settings and users, 
and especially by those metagenres specific to the genre system. 
Then I present the different genres and explore the textual properties 
and relations between genres, paying particular attention to two of the 
salient genres of the system, which are closely related: the summary of 
product characteristics (SPC) and the package leaflet (PL) in terms of their 
content and form. Finally, the intertextual operations that take place 
between the specialized genre and the lay-friendly genre are explored. For 
this last purpose, I illustrate the intralinguistic translation process from the 
SPC into the PL, taking the example of a particular medicinal product 
(VIAGRA 25 mg film-coated tablets), and using as a framework Montalt 
Resurreció and González Davis’ (2007) proposals on genre shift strategies 
and determinologization procedures. 
4. Description of the medicinal product information genre system 
The process of medicinal product information and promotion of a medicinal 
product for its marketing, sale and use implies a sequence of interrelated 
communicative actions structured in a genre system that I have called 
medicinal product information. 
Medicinal products are highly regulated in the European Union 
(EU). The dynamics of institutional interrelations among the genres 
involved are set out in a complicated system of metagenres issued by 
regulatory authorities such as regulations, directives and institutional 
guidelines. These govern how, when, where, and in what form such 
products will be allowed to be marketed and sold within the EU so as to 
safeguard and guarantee the highest possible level of public health and to 
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secure the availability of medicinal products to citizens (Directorate 
General for Health and Consumers (DGHC), 1986–2012b, chap. 2). Thus, 
the connections between the genres involved, the information given, the 
structuring devices, stylistic and linguistic aspects, and even translation 
matters, are standardized and normalized. 
The rules and regulations governing medicinal products for human 
use in the EU are collected in Volume 1 of The Rules Governing Medicinal 
Products in the European Union (DGHC, 1986–2012a). The legislation is 
supported by a series of guidelines addressed to professional writers and 
scientific staff which are compiled in Volume 2 of the same publication. 
Specifically, Volume 2C contains, among other things, a list of regulatory 
guidelines related to the full information to be included in the SPC and PL, 
stylistic matters and requirements for the readability of the labelling and PL 
(DGHC, 1986–2012b). These also have to be read in conjunction with other 
relevant guidelines, recommendations and templates developed by the 
Quality Review of Documents (QRD) group (European Medicines Agency 
(EMA), 1995–2012). Advertising and promotional material of medical 
products is also subject to strict and specific control measures and effective 
monitoring by the European and local authorities. 
The series of interrelated communicative actions structured in the 
genre system is enacted within and across pharmaceutical and medical 
communities, and its ultimate purpose is to facilitate the prescription of the 
medicine by the competent healthcare intermediaries and to secure its 
availability and safe use by patients. 
The range of participants involved in the process is very wide. They 
are: researchers, scientific staff, medical writers and linguistic mediators 
working directly or indirectly for pharmaceutical companies or the 
Marketing Authorization Holder (MAH), who generate the genre system 
and compose the various documents involved in the process; the authorities 
—mainly the European Medicines Agency (EMA), The Working Group on 
the Quality Review of Documents (QRD), and The Directorate General for 
Health and Consumers (DGHC) of the European Comission— which 
regulate and supervise the process; healthcare professionals (prescribers, 
dispensers, etc.) who are the competent intermediaries; and, finally, patients 
and the general public who use the product. The knowledge generated in 
laboratories and hospitals is distributed top-down (Montalt Resurrecció & 
González Davis, 2007, p. 46) and the scope of the involvement and 
responsibility of the various participants in the genre system is dissimilar. 
4.1. The genres of the medicinal product information genre system 
The main genres of the system are: the summary of product characteristics 
(SPC), the package leaflet (PL) and the labelling. Pharmaceutical 
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companies or MAHs are legally obliged to provide the SPC to prescribers 
and dispensers. MAHs must also ensure that medicines will reach patients 
and users accompanied by the PL and with the approved labelling (DGHC, 
1986–2012b). There are also other genres involved, such as the company 
core data sheet (CCDS), the company core safety information (CCSI), 
periodic safety update reports (PSURs), promotional texts, etc. This set of 
interdependent genres whose purpose, content, timing and form typically 
interconnect is implemented in a well-defined sequence that offers a wide 
spectrum of communicative situations of decreasing degrees of required 
expertise and formality.  
The central document, the summary of product characteristics 
(SPC), contains the essential information for healthcare professionals on 
how to use the medicinal product safely and effectively. It is written in 
accordance with the CCDS and the CCSI, which are prior documents 
containing all the relevant information concerning the product (DGHC, 
2009a). 
The SPC, in turn, is the document on which the patient information 
leaflet and the labelling are based. The package leaflet (PL), also known as 
patient information leaflet (PIL) or package insert, is the leaflet included in 
the pack with the medicine. It is a summarized and simplified patient-
friendly version of the SPC, and it has to be composed in such a way as to 
ensure that it is accessible to and readable by non-professionals, so that they 
can use their medicine safely and appropriately. 
Besides, any promotion of a medicine, advertising, press releases, 
etc. (when allowed) has to be drawn up in accordance with the SPC and 
must be within the terms of the most up-to-date SPC (DGHC, 1986–2012b, 
2008). 
In addition, there are a series of documents prepared by the MAH 
which are not always made available to the public and which have to be 
used as reference for periodic safe reporting and in the preparation of the 
SPC (DGHC, 2009a). The company core data sheet (CCDS) or core data 
sheet (CDS) is a summary of the key characteristics of the product. In 
addition to product information, it contains safety information and 
pharmacovigilance data. It also includes information on indications, dosing, 
pharmacology and other issues concerning the product. Many companies 
compile a product monograph or product profile that is quite similar to the 
CCDS and includes much if not all of the same information. A practical 
option for the purpose of periodic reporting is for each MAH to use the 
safety information contained within its major document (the CCDS) as a 
reference, and then create a new document: the company core safety 
information (CCSI). This document contains the pharmacovigilance section 
of the CCDS in its entirety or a summary of it. It is intended as the 
minimum safety information for the product in all the countries of the world 
where that product is marketed. A CCDS may be updated as necessary and 
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accompanies the periodic safety update reports (PSURs). PSURs present 
the worldwide safety experience of a medicinal product at defined times 
post-authorization (DGHC, 1986–2012a, 1986–2012b). 
Figure 1: Medicinal product information genre system template (adapted 
from Montalt Resurrecció & González Davis, 2007, p. 69) 
4.2. Summary of product characteristics and package leaflet: content 
and form 
The Summary of product characteristics has an agreed standard template 
which ensures consistent presentation of data across all SPC documents and 
enables the specialized reader to retrieve the information easily. The 
documents “A guideline on summary of product characteristics” (DGHC, 
2009a) and “Quality Review of Documents (QRD) human product 
information annotated template: revision of the product information” 
(Quality Review of Documents Group (QRD), 2012, pp. 4–8) provide the 
standardized headings, the phrase sets and phraseology that should be used 
and/or included when necessary, and give advice on the principles of 
presenting information. 
Sections 1 to 3 of the template contain pharmaceutical data; Sections 
4 and 5 contain clinical information (Section 4 relates to the clinical usage 
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of the medicine and Section 5 includes the relevant scientific information 
and pharmacological details); Section 6 contains pharmaceutical particulars, 
and Sections 7 to 10 include administrative information.  
Phraseological units are provided for all sections. For example: 
“<This medicinal product is for diagnostic use only.>”, “<Precautions to be 
taken before handling or administering the medicinal product>” (QRD, 
2012, pp. 4–8). 
Consistent medical terminology has to be used and the documents 
must be worded in clear, concise and unambiguous language. The use of the 
Medical Dictionary for Regulatory Activities (MedDRA) (2012) should be 
applied throughout the SPC, particularly for Sections 4.3, 4.4 and 4.8. The 
lists of the Standard Terms Database published by the European 
Directorate for the Quality of Medicines and Healthcare (EDQM) of the 
Council of Europe (2008) cover dosage forms, routes and/or methods of 
administration, and containers, closures and delivery devices used for 
medicines. The EDQM also provides standardized nomenclatures and 
quality standards for medicinal substances and products, which are 
published in the European Pharmacopoeia (EDQM, 2010).  
Package leaflets, too, have a standardized template where headings 
and sets of phraseological units are set down, such as: “Talk to your doctor 
<or> <,> <pharmacist> <or nurse> before <taking> <using> X”, “<The 
recommended dose is...>”, etc. (QRD, 2012, pp. 10–15).  
Other institutional guidelines on the readability of PLs contain 
indications on text type, size and font, the design and layout of the 
information, the print colour, syntax, style, paper weight, and use of 
images, etc. There are also specific recommendations for blind and 
partially-sighted patients (DGHC, 2008, 2009b). 
5. Summary of product characteristics and package leaflet genre shift 
The medicinal product information genre system description shows that the 
different genres in the system deal with the same topic, but they fulfil 
different functions and each of them covers specific reader needs. These 
textual relationships, called referential and functional intertextuality, are of 
relevance to the medical writer and translator (Montalt Resurrecció & 
González Davis, 2007, pp. 55–56) because they underline the fact that 
genres are dependent on each other as far as communication is concerned 
but have to be written according to different processes of rhetorical 
composition with decreasing degrees of specialization and formality. To 
illustrate these intertextual operations we have chosen two of the genres 
that are more closely related: the SPC and the PL. 
PLs are composed from SPCs in a translation process known as 
genre shift —also known as heterofunctional or transgeneric translation— 
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(Montalt Resurrecció & González Davis, 2007, p. 163) in which changes in 
rhetorical purpose and audience inevitably affect the texture and manner of 
re-presentation in predictable ways (Fahnestock, 1998). In this particular 
instance of intralinguistic genre shifting, the source genre, the SPC, is an 
expository genre addressed to experts and professionals, and the target 
genre, the PL, is an instructional genre addressed to lay readers. Genre 
shifting is used to bridge the gap between the patient’s right to know and 
the patient’s ability to understand, and guarantees the continuity of 
communication between different expertise communities.  
If we put the templates of both genres (QRD, 2012, pp. 4–8, 10–15, 
presented as Tables 2 and 3 in the Appendix) side by side, we can observe 
that major structural changes are introduced, PLs are simpler and shorter. 
The information on pharmaceutical data in Sections 1 to 3 of the SPC is 
presented in different places, mainly at the end of the PL (Section 6), and 
sometimes more than once. In PLs the information on clinical particulars 
(Section 4 of the SPC) goes at the beginning of the PL (Sections 1 to 3). 
Relevant scientific information, pharmacological properties and 
pharmaceutical details in SPCs (Sections 5 and 6) are reduced to the 
minimum in PLs.  
Table 1: Comparison of SPC and PL templates 
SPC PL 
1. Name of the medicinal product {(Invented) name strength 
pharmaceutical form} 
2. Qualitative and quantitative composition {Active substance(s)}  
6. Contents of the pack and other 
information  
What X contains  
3. Pharmaceutical form [6.] What X looks like and 
contents of the pack 
4. Clinical particulars  
4.1 Therapeutic indications  
1. What X is and what it is used 
for  
4.2 Posology and method of administration 3. How to <take> <use> X  
4.3 Contraindications 2. What you need to know before 
you <take> <use> X 
Do not <take> <use> X<:> 
4.4 Special warnings and precautions for use [2.] Warnings and precautions 
4.5 Interaction with other medicinal products 
and other forms of interaction 
[2.] Other medicines and X 
4.6 Fertility, pregnancy and lactation [2.] Pregnancy <and> <,> breast-
feeding <and fertility> 
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4.7 Effects on ability to drive and use 
machines 
[2.] Driving and using machines 
4.8 Undesirable effects 
<Paediatric population> 
4. Possible side effects 
<Additional side effects in 
children <and adolescents>> 
4.9 Overdose [3.] <If you <take> <use> more X 
than you should>  
5. Pharmacological properties 
5.1. Pharmacodynamic properties 
5.2. Pharmacokinetic properties 
5.3. Preclinical safety data 
 
6. Pharmaceutical particulars 
6.1. List of excipients 
6.2. Incompatibilities 
6.3. Shelf life 
6.4. Special precautions for storage 
6.5. Nature and contents of container  <and 
special equipment for use, administration or 
implantation> 
6.6. Special precautions for disposal <and 
other handling> 
6. Contents of the pack and other 
information  
What X contains 
 
5. How to store X 
7. Marketing authorization holder [6.] Marketing Authorization 
Holder and Manufacturer 
8. Marketing authorization number(s)  
9. Date of first authorization/renewal of the 
authorization 
 
10. Date of the revision of the text [6.] This leaflet was last revised in 
<{MM/YYYY}> <{month 
YYYY}.> 
As Montalt Resurrecció and González Davis point out (2007, pp. 162–164), 
besides structural simplification, there are other procedures used by 
linguistic mediators when genre shifting specialized genres into genres for 
patients:  
• Synthesizing information. 
• Expanding relevant information for the target reader.  
• Shifting from author and content to reader comprehension.  
• Adjusting tenor to achieve more personalized communication.  
• Simplifying syntax. 
• Using verbs instead of complicated nouns or noun phrases.  
• Determinologizing complex terms.  
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In order to illustrate the shifts introduced and the procedures employed 
when genre shifting SPCs into PLs, we will compare the original SPC and 
the target PL of a particular medicinal product, VIAGRA 25 mg film-coated 
tablets (Pfizer Limited, 2009–2010), putting different examples of original 
fragments of the SPC and the mediated corresponding fragments of the PL 
side by side.  
In Example 1 below, information concerning clinical usage of the 
medicine, pharmaceutical particulars and pharmacological details of the 
SPC is synthesized to the minimum in the PL, and content focus third 
person declarative mode of the SPC is translated into second person factual 
conditional in the PL: “if you are… your doctor may”. Thus, the missing 
information in PL and any possible action will be handled by the reader of 
the SPC, the doctor. The reader of the PL is considered a non-powerful 
participant and any interpretation and form of action by patients is 
excluded. 
Also, the passive sentence “co-administration of sildenafil with 
ritonavir is not advised” and the negative wording “in any event the 
maximum dose of sildenafil should under no circumstances exceed 25 mg 
within 48 hours” are translated into an active positive sentence: “your 
doctor may start you on the lowest dose (25 mg) of VIAGRA”. 
Example 1 
[SPC] 
[4.5 Interaction with other 
medicinal products and other 
forms of interaction] 
Co-administration of the HIV 
protease inhibitor ritonavir, which 
is a highly potent P450 inhibitor, 
at steady state (500 mg twice 
daily) with sildenafil (100 mg 
single dose) resulted in a 300% 
(4-fold) increase in sildenafil 
Cmax and a 1,000% (11-fold) 
increase in sildenafil plasma 
AUC. At 24 hours, the plasma 
levels of sildenafil were still 
approximately 200 ng/ml, 
compared to approximately 5 
ng/ml when sildenafil was 
administered alone. …  
[PL] 
[2.] [Taking other medicines:] 
If you are taking medicines known 
as protease inhibitors, such as for 
the treatment of HIV, your doctor 
may start you on the lowest dose 
(25 mg) of VIAGRA.  
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[SPC] 
This is consistent with ritonavir’s 
marked effects on a broad range 
of P450 substrates. Sildenafil had 
no effect on ritonavir 
pharmacokinetics. Based on these 
pharmacokinetic results co-
administration of sildenafil with 
ritonavir is not advised […] and 
in any event the maximum dose 
of sildenafil should under no 
circumstances exceed 25 mg 
within 48 hours. 
 
When shifting from author and content to reader comprehension, to 
facilitate the PL’s readability, other changes are also introduced, as in 
Examples 2, 3, 4 and 5. In the next example, the information listed in the 
SPC is translated into descriptive full sentences. In addition, the heading 
“Pharmaceutical form” of the SPC is expanded into the PL’s heading 
“What VIAGRA looks like and contents of the pack”: 
Example 2 
[SPC] 
[3. PHARMACEUTICAL 
FORM] 
Film-coated tablet. 
Blue rounded diamond-shaped 
tablets, marked “PFIZER” on one 
side and “VGR 25” on the other. 
[PL] 
[[6.] What VIAGRA looks like and 
contents of the pack] 
VIAGRA film-coated tablets are 
blue, with a rounded-diamond 
shape. They are marked “PFIZER” 
on one side and “VGR 25” on the 
other side.  
In Example 3 below, relevant information for the target reader is clarified. 
As in “for oral use” translated as “Swallow the tablet whole with a glass of 
water”. Also, technical terms like “posology”, “toleration”or “indicated” 
are omitted. Complete sentences are used instead of noun phrases; for 
example: “sexual activity” is translated as “you plan to have sex”. 
Moreover, imperatives, bold type and modality are used to increase the 
degree of obligation and to express emphasis and caution, as in: “you 
should…”, “you may find…”, or in the sentence “Viagra is not indicated 
for” rewritten as “Viagra should not be given to”: 
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Example 3 
[SPC] 
4.2 Posology and method of 
administration 
For oral use.  
Use in adults:  
The recommended dose is 50 mg 
taken as needed approximately 
one hour before sexual activity. 
Based on efficacy and toleration, 
the dose may be increased to 100 
mg or decreased to 25 mg. The 
maximum recommended dose is 
100 mg. The maximum 
recommended dosing frequency is 
once per day. If VIAGRA is taken 
with food, the onset of activity 
may be delayed compared to the 
fasted state. 
[…] 
Use in children and adolescents 
VIAGRA is not indicated for 
individuals below 18 years of age.  
[PL] 
3. HOW TO TAKE VIAGRA 
Always take VIAGRA exactly as 
your doctor has told you. […] The 
usual starting dose is 50 mg. 
You should not take VIAGRA 
more than once a day. 
You should take VIAGRA about 
one hour before you plan to have 
sex.  
Swallow the tablet whole with a 
glass of water. 
[…] 
You may find that VIAGRA takes 
longer to work if you take it with a 
heavy meal. 
[…] 
Special considerations for children 
and adolescents 
VIAGRA should not be given to 
individuals under the age of 18. 
 
In the following example we can observe how specialized terms are dealed 
with so that a non-specialist reader can understand them. The characteristic 
nominalization of scientific language, for example, “contraindications”, 
“hypersensitivity”, is translated into full imperative sentences: “Do not take 
Viagra”, “If you are allergic (hypersensitive)”. Also, the medical term 
“hypersensitive” is retained but in parenthesis after the popular term 
“allergic”: 
Example 4 
[SPC] 
4.3 Contraindications 
Hypersensitivity to the active 
substance or to any of the 
excipients. 
[PL] 
Do not take VIAGRA 
–  If you are allergic (hypersensitive) 
to sildenafil or any of the other 
ingredients of VIAGRA. 
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To achieve a more personalized communication, the tenor is adjusted in 
PLs, the language is more personal and the passive is less frequent. In 
Example 5, we can notice that the degree of formality decreases (e.g., 
“penile erection” translated as “to get or keep a hard, erect penis”, 
“satisfactory sexual performance” translated as “sexual activity”). Also, the 
personal pronoun “you” is introduced in the passive form: “sexual 
stimulation” is translated as “you are sexually stimulated”. 
Example 5 
[SPC] 
4. CLINICAL PARTICULARS 
4.1 Therapeutic indications  
Treatment of men with erectile 
dysfunction, which is the inability 
to achieve or maintain a penile 
erection sufficient for satisfactory 
sexual performance. 
In order for VIAGRA to be 
effective, sexual stimulation is 
required. 
 
[PL] 
1. WHAT VIAGRA IS AND 
WHAT IT IS USED FOR  
VIAGRA is a treatment for men 
with erectile dysfunction, 
sometimes known as impotence. 
This is when a man cannot get, or 
keep a hard, erect penis suitable for 
sexual activity. 
VIAGRA will only help you to get 
an erection if you are sexually 
stimulated. 
As we have mentioned, when the context of communication of medical 
knowledge moves from specialists to the general public, terminology, 
which is a quick, clear and precise way of transmitting information for the 
specialist, may hinder comprehension for the lay reader. 
Determinologization is therefore a requirement. Montalt Resurrecció and 
González Davis (2007, pp. 252–253) state that the determinologization 
procedures that can be used by translators and medical writers when, for 
example, producing press releases from medical research articles, include 
the following:  
• Scientific terms are retained and followed by explanations.  
• Scientific terms are retained in parentheses after the explanations. 
• Scientific terms are followed by popular terms. 
• Scientific terms are completely avoided and replaced by 
explanations. 
In the process of genre shifting from SPCs into PLs a comprehensive 
operation of determinologizing the original text is also required of the 
linguistic mediators. In our example of VIAGRA 25 mg film-coated tablets 
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(Pfizer Limited, 2009–2010) we can find instances of the following 
determinologization procedures: 
• Scientific terms retained and followed by explanations and/or 
popular terms: the phrase “patients who have conditions which may 
predispose them to priapism (such as sickle cell anaemia, multiple 
myeloma or leukaemia)” in the SPC is translated as “If you have 
sickle cell anaemia (an abnormality of red blood cells), leukaemia 
(cancer of blood cells), multiple myeloma (cancer of bone marrow)” 
in the PL.  
• Scientific terms retained after the explanations in the PL, as in “If 
you are allergic (hypersensitive)” or “If you have a deformity of your 
penis or Peyronie’s Disease”. 
• Scientific terms followed and/or accompanied by popular terms in 
the PL, as in “angina pectoris (or ‘chest pain’)”, “the drugs known as 
nitric oxide donors such as amyl nitrite (‘poppers’)”, or “If you have 
a deformity of your penis or Peyronie’s Disease”. 
• Scientific terms completely avoided and replaced by popular terms: 
for example, “Impaired renal function” in the SPC becomes “kidney 
problems” in the PL; and “Impaired hepatic function” in the SPC is 
determinologized as “liver problems” in the PL. 
As a summary, we can state that the different shifts observed when genre 
shifting from SPCs into PLs are: 
• Shifts that are intended to facilitate the PL’s readability for patients. 
• Shifts that are intended to exercise control over patients’ actions and 
that have power implications. 
• Shifts that personalize communication and try to get closer to 
readers. 
6. Conclusions 
In this study, I propose that the notion of genre systems can be a valuable 
analytic device for studying the roles played by the context and the different 
agents involved in complex communicative actions such as the medicinal 
product information, and a means to provide medical writers and translators 
with the contextual and textual information that their task requires. Our 
purpose here is to help to illustrate how genre systems description can be 
used to adress the multifaceted issue of medicinal product information.  
I have described the medicinal product information genre system, 
focusing on how metagenres interact with the genre system, how they 
regulate the interrelations and sequence of the constituent genres, and how 
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they contribute to stabilizing the content and form of communicative 
product information practices, paying special attention to two of the salient 
and more closely related genres, the SPC and the PL. 
The system as a whole, as well as the individual genres, can be said 
to have a socially recognized purpose and common formal characteristics. It 
is suggested that the contextual knowledge of these dimensions and of the 
institutional operations of metagenres can benefit and play an important 
role in the socialization of medical writers and linguistic mediators as 
communicative agents of the pharmaceutical sector.  
To approach the way in which textual competence should be 
acquired and applied by linguistic mediators, the intertextual operations that 
take place between the specialized genre and the lay-friendly genre have 
been explored. Our method here is not corpus-based; we have rather 
illustrated the genre shift or intralinguistic transgeneric translation process 
from the SPC into the PL, both genres belonging to the medicinal product 
information genre system, taking the example of a particular medicinal 
product (VIAGRA 25 mg film-coated tablets). Although the mediator’s 
decisions in the process of genre shifting from SPCs into PLs are restricted 
by norms and rules, there are certain areas that offer scope for rhetorical 
composition, which are governed in turn by the communicative needs and 
purposes of PLs. I have identified different types of shift; and genre-shifting 
strategies and determinologization procedures have been illustrated. It is 
suggested that they may be used by (prospective) professional medical 
writers and translators to work more efficiently and to achieve the intended 
communicative function of the texts produced. However, further corpus-
based analysis will be needed to consolidate (or extend) the list of strategies 
and procedures identified. Also, the power implications that we have just 
pointed out and that may underlie the shift from the specialized into the lay-
friendly genre will require a more careful consideration. 
This study may also contribute to the development of conceptual and 
cognitive resources for researchers interested in medical communication 
processes, and to the improvement of tools for the teaching and acquisition 
of medical writing and translation competence, in its formal, social and 
cognitive aspects. 
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Appendix 
Table 2: Summary of product characteristics template (QRD, 2012, pp. 4-8) 
SUMMARY OF PRODUCT CHARACTERISTICS 
 
1. Name of the medicinal product 
2. Qualitative and quantitative composition 
3. Pharmaceutical form 
4. Clinical particulars 
4.1. Therapeutic indications 
4.2. Posology and method of administration 
4.3. Contraindications 
4.4. Special warnings and precautions for use 
4.5. Interaction with other medicinal products and other forms of interaction 
4.6. Fertility, pregnancy and lactation 
4.7. Effects on ability to drive and use machines 
4.8. Undesirable effects 
4.9. Overdose 
5. Pharmacological properties 
5.1. Pharmacodynamic properties 
5.2. Pharmacokinetic properties 
5.3. Preclinical safety data 
6. Pharmaceutical particulars 
6.1. List of excipients 
6.2. Incompatibilities 
6.3. Shelf life 
6.4. Special precautions for storage 
6.5. Nature and contents of container <and special equipment for use, 
administration or implantation> 
6.6. Special precautions for disposal <and other handling> 
7. Marketing authorization holder 
8. Marketing authorization number(s) 
9. Date of first authorization/renewal of the authorization 
10. Date of the revision of the text 
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Table 3: Package leaflet template (QRD, 2012, pp. 10-15) 
Package leaflet: Information for the <patient> <user> 
{(Invented) name strength pharmaceutical form} 
 
What is in this leaflet 
1. What X [the medicine] is and what it is used for 
2. What you need to know before you <take>  <use> X 
Do not <take> <use> X<:> 
Warnings and precautions 
Children <and adolescents>  
Other medicines and X 
X with <food> <and> <,> <drink> <and> <alcohol>  
Pregnancy <and> <,> breast-feeding <and fertility> 
Driving and using machines  
<X contains {name the excipient(s)}> 
3. How to <take>  <use> X 
<Use in children <and adolescents>> 
<If you <take> <use> more X than you should> 
<If you forget to <take> <use> X> 
<If you stop <taking> <using> X> 
4. Possible side effects 
<Additional side effects in children <and adolescents>> 
5. How to store X 
6. Contents of the pack and other information 
What X contains 
What X looks like and contents of the pack  
Marketing Authorization Holder and Manufacturer 
This leaflet was last revised in <{MM/YYYY}> <{month YYYY}.> 
<Other sources of information> 
 
_____________________________ 
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